Amanda K. Antons, Ph.D.’s practice focuses on patent litigation, specifically in the pharmaceutical and biotechnology industries, including biologics litigation, Abbreviated New Drug Application litigation, Patent Trial and Appeal Board proceedings, European Patent Office proceedings, other contentious patent office matters including interferences, and related trade secrets litigation. Her doctoral training, including work on T cell/HIV interactions, provides her with significant research experience and knowledge in the biotechnology and life sciences industries. Her cases have dealt with a wide variety of technologies, including monoclonal antibodies (e.g., ixekizumab, adalimumab, anti-PD-1/L1 antibodies), and other biologics (e.g., AAV viral vectors, aflibercept, CRISPR, epopoietin), peptides (e.g., insulin glargine, daptomycin), DNA sequencing and small-molecule therapeutics.
Dr. Antons also has experience counseling clients regarding patent portfolio evaluation, including conducting diligences regarding validity of biologics patents and the freedom to operate new technologies. In 2024, Dr. Antons was listed by The Legal 500 US for Intellectual Property: Patents: Litigation, being described as “highly experienced in ANDA litigation.” She was also recognized as “One to Watch” by The Best Lawyers in America 2025 for Patent Litigation and as a “Rising Star” for General Patent Litigation by LMG Life Sciences 2024. In 2023, Dr. Antons was named a Profiles in Diversity Journal Woman Worth Watching in STEM, as well as a 2023 Rising Star by Managing Intellectual Property.
-
- DePaul University College of Law, J.D., 2011, magna cum laude and order of the coif
- Vanderbilt University, Ph.D., microbiology and immunology, 2008
- Iowa State University, B.S., agricultural biochemistry, 2003
-
- Illinois
- United States Patent and Trademark Office
- United States Court of Appeals for the Federal Circuit
- United States District Court for the Northern District of Illinois